News - Par Pharmaceutical, North America

Filter

Popular Filters

Horizon Pharma in Duexis patent settlement

22-08-2013

Horizon Pharma (Nasdaq: HZNP) says it has entered into settlement and license agreements with Par Pharmaceutical…

Anti-Arthritics/RheumaticsDuexisGenericsHorizon PharmaNorth AmericaPar PharmaceuticalPatentsPharmaceutical

Par Pharma agrees $45 million settlement over off-label Megace ES promotion

07-03-2013

US generic drugmaker Par Pharmaceutical NYSE: PRX) pleaded guilty in federal court yesterday (March 6)…

FinancialGenericsLegalMarkets & MarketingMegace ESMetabolicsNorth AmericaPar PharmaceuticalPharmaceutical

Validity of certain patent claims covering Santarus' Zegerid capsule and powder upheld

06-09-2012

US drugmaker Santarus (Nasdaq: SNTS) saw its shares leap 14.2% to $7.06 in regular trading on September…

GenericsLegalNorth AmericaPar PharmaceuticalPatentsPharmaceuticalSantarusZegerid

Mylan settles litigation with Somaxon relating to its generic Silenor

19-07-2012

US generic drugmaker Mylan (Nasdaq: MYL) and its subsidiary, Mylan Pharmaceuticals have entered into…

LegalMylan LaboratoriesNeurologicalNorth AmericaPar PharmaceuticalPatentsPharmaceuticalSilenorSomaxon Pharmaceuticals

FDA decides Teva is sole first-to-file on Provigil; Mylan argues ruling

09-04-2012

Israel-based Teva Pharmaceutical Industries (Nasdaq: TEVA) said on April 5 that the US Food and Drug…

CephalonGenericsLegalModafinilMylan LaboratoriesNeurologicalNorth AmericaPar PharmaceuticalProvigilRegulationTeva Pharmaceutical Industries

Horizon Pharma sues Par for infringing Duexis patent

29-03-2012

Horizon Pharma (Nasdaq: HZNP) has filed a patent infringement lawsuit in the US District Court for the…

DuexisGenericsHorizon PharmaLegalNeurologicalNorth AmericaPar PharmaceuticalPatents

Back to top